AstraZeneca Results Presentation Deck

Emerging markets Diverse and solid growth $m 3,000 2,500 2,000 1,500 1,000 500 Q1 2018 Q2 2018 Q3 2018 Emerging markets +10% EMs ex China +11%; China +10% Q4 2018 Q1 2019 Q2 2019 Q3 2019 China EMs ex China Total revenue at actual exchange rates; changes at CER and for Q1 2021, unless stated otherwise. 18 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Performance driven by new medicines up 30% (34% of total revenue; $0.9bn¹) Oncology +4%: Tagrisso (+5%) ; March 2021 NRDL inclusion. New CVRM +41% : Forxiga (+85%); roxadustat ($41m) Respiratory & Immunology -4%: Pulmicort ($286m, -14%), but Symbicort continued up ($165m, +3%) Diversified growth: AP2 stable, MEA³ +26%, LA4 +10%, Russia +7% 2021 China patient access: major NRDL inclusion Tagrisso 1st line and VBP5 impact to Brilinta, Nexium, other tail medicines Revenue anticipated to continue growing ahead of the long-term ambition of mid to high single-digit growth Total revenue at actual exchange rates; changes at CER and for Q1 2021, unless stated otherwise. 1. Total revenue at CER 2. Asia Pacific 3. Middle East, Africa and other 4. Latin America 5. Volume-based procurement. 3

View entire presentation